Bayer Eyes Indications Beyond BlueRock's Initial Focus With $240m-Plus Buyout
Bayer will acquire the 40.8% of BlueRock that it doesn't already own as the firm's largest investor via a $225m series A round in 2016. A clinical trial for BlueRock's Parkinson's disease candidate is expected to begin later this year.
You may also be interested in...
The major will use funds from the sale of its male hypogonadism product to invest in future innovation, which is likely to focus on high-risk high-reward cell and gene drug candidates.
The German major will collaborate with the US biotech to develop CRISPR gene-editing therapies, solidifying its interest in next-generation therapeutics.
It has taken just seven weeks from a cold call to completion and the German major has got its hands on a prized asset in Vividion which was on the verge of listing on the NASDAQ. The companies told Scrip how the deal was done.